View Exam | PowerPak

1. Which of the following oral tyrosine kinase inhibitors was approved in 2020 for the treatment of HER2+ breast cancer?

A. Capmatinib B. Pertuzumab, trastuzumab, hyaluronidase-zzxf C. Sactuzumab govitecan-hziy D. Tucatinib E. Unsure

2. Which of the following drugs, approved in 2020, is the first therapy approved for upper tract urothelial cancer?

A. Avelumab B. Mitomycin C. Lurbinectedin D. Pembrolizumab E. Unsure

3. Which of the following is the appropriate extended dosing interval approved in 2020 for pembrolizumab?

A. 480 mg every 4 weeks B. 1500 mg every 4 weeks C. 1680 my every 4 weeks D. 400 mg every 6 weeks E. Unsure

4. Which of the following drugs receive a tumor-agnostic indication in 2020 for patients with unresectable or metastatic solid tumors with high mutational tumor burden?

A. Entrectinib B. Larotrectinib C. Nivolumab D. Pembrolizumab E. Unsure

5. Which of the following statements is true about treatment of extensive-stage small cell lung cancer?

A. Atezolizumab maintenance therapy following 4 cycles of carboplatin or cisplatin + etoposide is standard of care first-line therapy for extensive-stage small cell lung cancer B. Durvalumab maintenance therapy following 4 cycles of carboplatin or cisplatin + etoposide + durvalumab is standard of care first-line therapy for extensive-stage small cell lung cancer C. Lurbinectedin is recommended as preferred treatment option for patients who relapse more than 6 months after first-line therapy D. Selpercatinib is recommended for patients with RET fusion-positive extensive-stage small cell lung cancer E. Unsure

6. Which of the following significant changes were observed in the treatment of bladder cancer in 2020?

A. Maintenance therapy with the checkpoint inhibitor, avelumab, is now standard of care following platinum-based chemotherapy in metastatic muscle-invasive bladder cancer B. Mitomycin ureteral gel is now recommended as a first-line therapy for treatment of all upper tract urothelial carcinomas C. Maintenance therapy with the checkpoint inhibitor pembrolizumab is the now recommended in all patients with nonmuscle invasive bladder cancer D. Olaparib is now recommended for all patients with bladder cancers that have BRCA mutations who have failed first-line therapy E. Unsure

7. Which of the following monoclonal antibody product requires receipt of 1 full dose of the intravenous monoclonal antibody before receiving this subcutaneous formulation?

A. Daratumumab + hyaluronidase-fihj B. Pertuzumab + trastuzumab + hyaluronidase-zzxf C. Rituximab + hyaluronidase D. Trastuzumab + hyaluronidase-oysk E. Unsure

8. Which of the following monoclonal antibody products requires premedication with an H1 receptor antagonist, acetaminophen, and a corticosteroid?

A. Daratumumab + hyaluronidase-fihj B. Pertuzumab + trastuzumab + hyaluronidase-zzxf C. Rituximab + hyaluronidase D. Trastuzumab + hyaluronidase-oysk E. Unsure

9. Which of the following statements is true about patients with cancer and COVID-19?

A. All patients with cancer receiving active treatment are required to have a negative COVID-19 test before receiving treatment. B. During a pandemic such as COVID-19, all patients receive active therapy for treatment of metastatic disease should have care interrupted until the local positivity rates of COVID-19 are <5%. C. Evidence supports the use of prophylactic antiviral therapy with remdesivir in immunosuppressed patients. D. Remdesivir and dexamethasone may be used to treat COVID-19 in patients with cancer. E. Unsure

10. Which of the following is an American Society of Clinical Oncology recommendation about central venous catheters in patients with cancer during COVID-19?

A. A COVID-19 test should be negative before patient is given permission to flush their own central venous catheter. B. Flushing interval can be extended to 12 weeks C. Only trained health care professionals should flush central venous catheters. D. Central venous catheters should not be placed until the pandemic has ceased. E. Unsure